siRNA/ASO/Biomarker Quantification and Statistical Analysis

Over the last three decades small interfering ribonucleic acid (siRNA) and antisense oligonucleotide (ASO) have merged as powerful tools to modulate the expression of genes in vivo and in vitro. RNA-mediated drugs are a rapidly growing class of therapeutics. Despite its great promise, RNA-based therapy is challenging because of issues related to stability and delivery of RNA. There are multiple barriers to its delivery that depend on administration route and targeted organs. So, determining the siRNA/ASO distribution is central for the efficiency and safety assessment of proposed early-phase clinical trials.

RNA ISH assay from Creative Bioarray allows visualization and quantification of siRNA/ASO presence, and biomarker expression in treated tissue samples. We are capable of offering siRNA/ASO/Biomarker Quantification and Statistical Analysis service in the most high-quality and cost-effective way. And the service can help you validate and accelerate your gene therapy development.

Benefits of siRNA/ASO/Biomarker Quantification and Statistical Analysis

(1) siRNA/ASO+ cell detection and quantification in intact fixed tissue
(2) Quantifiable assays to measure percentage of cells positive for siRNA/ASO and biomarker expression

Quotation and ordering

Our customer service representatives are available 24hr a day! We thank you for considering Creative Bioarray as your siRNA/ASO/Biomarker Quantification and Statistical Analysis partner.

References

1. Kole, R.; Krainer, A.R.; Altman, S. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 2012, 11, 125–140.
2. Aagaard, L.; Rossi, J.J. RNAi therapeutics: Principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59, 75–86.
3. Goto, Akihiko, Syunsuke Yamamoto, and Shinji Iwasaki. "Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives." Biopharmaceutics & Drug Disposition 44.1 (2023): 26-47.